Sinan Ersan - research works

After propensity score matching, each routine cataract surgery cohort (with and without MIGS) comprised 7, 998 patients.

Similar associations were observed among patients undergoing routine or complex CE/IOL combined with MIGS compared with those undergoing routine or complex CE/IOL alone with respect to hyphema, CME, and RD.

A total of 2,050 infants met inclusion criteria.

Bevacizumab decreased from 100% of all intravitreal injections to 76.7% ( P < .0001).

Aflibercept use increased from 0% to 18.8% ( P < .0001).

White infants were more likely to be treated with intravitreal anti-VEGF than Black or Hispanic infants ( P = .0061).

A total of 2,912 patients on conventional IMT, 736 patients on biologic therapy and 1,313 on combination therapy met the definition of steroid-sparing control.

No difference in the rate of flares was found between combination versus biologic therapy, or conventional IMT versus biologic therapy at 6-, 12-, 18- and 24 months.

Patients initially treated with conventional IMT had higher rates of augmentation or switching to biologic therapy at 12 months (RR 1.74; p = 0.0386), 18 months (RR 1.65; p = 0.0219) and 24 months (RR 1.65; p = 0.0114).